Trade Report: The Alnylam Pharmaceuticals Inc. (ALNY) Downgraded by Needham & Company LLC to Buy

The Alnylam Pharmaceuticals Inc. (ALNY) Downgraded by Needham & Company LLC to Buy

Needham & Company LLC downgraded shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to a buy rating in a research note released on Thursday. The brokerage currently has $137.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $152.00.

Several other brokerages have also recently commented on ALNY. Cowen and Company reissued a buy rating and issued a $150.00 price target on shares of Alnylam Pharmaceuticals in a research report on Sunday, August 7th. Jefferies Group set a $86.00 price target on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, September 28th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 28th. They issued a neutral rating and a $74.00 price target for the company. Goldman Sachs Group Inc. reissued a neutral rating and issued a $65.00 price target (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Finally, Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a sell rating to a buy rating and set a $85.00 price objective for the company in a research report on Tuesday, August 9th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $85.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.69% during midday trading on Thursday, reaching $34.51. 2,828,885 shares of the company’s stock traded hands. The company’s market capitalization is $2.96 billion. The firm’s 50 day moving average price is $71.80 and its 200-day moving average price is $66.24. Alnylam Pharmaceuticals has a 1-year low of $34.18 and a 1-year high of $110.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter last year, the company posted ($0.85) EPS. The firm’s revenue was up .2% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.

In other news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.00% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in ALNY. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $128,000. Seven Eight Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $175,000. Bank of Montreal Can acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $193,000. Finally, BlueMountain Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Related posts

Leave a Comment